Historically, cancer treatment relied heavily on chemotherapy and radiation because tumors arise from the body’s own cells and can evade or suppress immune detection, making it difficult for T cells to effectively recognize and eliminate them.

In 2012, researchers at the University of Pennsylvania, led by Dr. Carl June, demonstrated a breakthrough approach by genetically engineering a patient’s own T cells to recognize a specific marker on cancer cells, enabling targeted immune attack.

Seven-year-old Emily Whitehead becomes the first pediatric patient to receive experimental T cells genetically modified to target CD19 on her B-cell leukemia, leading to her remission.

The Identification Problem
B-cell leukemia survives because the cancer cells do not trigger a T cell response. They often lack the specific surface signals the immune system requires to initiate a kill command. Emily had relapsed twice based on the use of traditional chemo.
Writing the New Code
Researchers use a viral vector to insert a new genetic sequence into the T cell. This sequence produces a Chimeric Antigen Receptor (CAR) on the cell's surface. The receptor is engineered to bind to the CD19 protein, a marker found on B-cell leukemia.
Manufacturing the Army
The process began with apheresis, filtering Emily’s blood to collect T cells. These cells were modified in a lab and grown into a population of millions before being infused back into the patient.
Managing the Immune Response
The infusion triggered a Cytokine Release Syndrome (CRS), a systemic inflammatory response. During the trial, doctors successfully used tocilizumab, an existing arthritis drug, to suppress the inflammation without stopping the T cells from destroying the tumor.
Remission
Emily remained in remission, founded a non-profit, and is now a student at the University of Pennsylvania.
The New Standard
CAR-T therapy is now an FDA-approved treatment for several blood cancers. It has transformed terminal diagnoses into cases with a high probability of durable remission.

From Brian

The current frontier for this technology is moving beyond liquid blood cancers. Clinical trials are now targeting solid tumors, such as glioblastoma and lung cancer, where the primary challenge is engineering cells to penetrate a suppressive tumor environment. Simultaneously, researchers are applying CAR-T to autoimmune diseases like Lupus, using the cells to eliminate the specific B cells responsible for the disease.

I highly suggest watching the inspiring movie “Of Medicine and Miracles,” which chronicles the intersecting journeys of Emily Whitehead and her incredible family, and Dr. Carl June and the team that saved her life, and those of so many others.

Read On LinkedIn

<- Previous

[year of previous innovation]

[name of previous innovation]

Next ->

[year of next innovation]

[name of next innovation]